KPV: The Tiny Anti-Inflammatory Peptide Derived From α-MSH

KPV is one of the smallest peptides in the whole research-peptide conversation: just three amino acids, lysine, proline, and valine, clipped from the tail end of a natural hormone called α-MSH. Despite its size, it has drawn real scientific attention because it appears to carry most of that hormone's anti-inflammatory punch while leaving behind the pigment-darkening and appetite effects. The honest catch is the same one that follows most of these compounds: almost all of the evidence is preclinical, there is essentially no human trial data, and KPV is sold only as an unapproved research chemical.

If you arrived here because KPV keeps coming up alongside gut health, skin inflammation, or "calming the immune system," this guide is the high-level map of the whole compound, and it sits among the options in our best peptides for recovery roundup. We cover what it actually is, where it comes from in α-MSH biology, how its proposed anti-inflammatory mechanism works, what it is studied for, the dosing ranges people report, the honest safety and legal picture, and how it differs from the repair-focused peptide it is most often confused with. Each section is a clear overview; the deepest sub-questions point to dedicated guides so this page stays a clean hub.

Key Takeaways

• KPV is a tripeptide made of lysine, proline, and valine (Lys-Pro-Val), the C-terminal fragment (residues 11 to 13) of the hormone α-melanocyte-stimulating hormone, with the molecular formula C₁₆H₃₀N₄O₄ (PubChem, "Compound Summary for CID 125672 (MSH 11-13)", retrieved 2026-06-16).
• Its headline property is anti-inflammatory activity. In a 2007 review, KPV is described as retaining the anti-inflammatory effects of α-MSH, in part by inhibiting NF-κB signaling and downregulating pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α (Annals of the Rheumatic Diseases, 2007).
• The strongest preclinical data are in the gut. In a 2008 study, KPV was shown to enter intestinal cells through the PepT1 transporter and to reduce inflammation in mouse models of colitis (Gastroenterology, 2008).
• It is also studied in skin and antimicrobial contexts, including a 2025 keratinocyte study where KPV reduced inflammation by modulating the MAPK and NF-κB pathways (Wikipedia, "KPV tripeptide", retrieved 2026-06-16).
• Human evidence is essentially absent. KPV has no FDA-approved use, no completed human efficacy trials surfaced, and it is sold "for research use only," so it should be treated as investigational (Wikipedia, "KPV tripeptide", retrieved 2026-06-16).
• Reported research and community doses cluster around 200 to 500 mcg per day by subcutaneous injection, with oral and topical use also discussed. These are community conventions, not validated dosing.

What is KPV?

KPV is a tripeptide, a chain of just three amino acids (lysine, proline, and valine), that comes from the tail end of the hormone α-MSH and is studied mainly for its anti-inflammatory effects. It is sometimes written as Lys-Pro-Val or "MSH (11-13)," reflecting that it is the last three residues of that larger hormone. It is studied most in gut inflammation and skin contexts.

Chemically, KPV is a short peptide with the molecular formula C₁₆H₃₀N₄O₄ and a molar mass of roughly 342 g/mol, identified in chemical databases under PubChem CID 125672 and CAS number 67727-97-3 (PubChem, "Compound Summary for CID 125672 (MSH 11-13)", retrieved 2026-06-16). The most interesting thing about it is how small it is: where many research peptides have a dozen or more amino acids, KPV has three, which is part of why researchers were surprised that it kept so much of α-MSH's biological activity. If injectable peptides and the basics of how short chains like this behave are new to you, start with our how peptides work guide.

The single most important fact about KPV is the same as for its better-known cousins: it is not approved by the FDA or any other drug regulator for any use. It exists in a modest body of preclinical research and, separately, in an unapproved "research chemical" market. Everything else in this guide should be read through that lens.

Citation capsule. KPV is a tripeptide (lysine-proline-valine; Lys-Pro-Val), the C-terminal tripeptide of α-melanocyte-stimulating hormone (residues 11 to 13), with molecular formula C₁₆H₃₀N₄O₄ and molar mass ≈342 g/mol. It is studied preclinically as an anti-inflammatory agent and is not approved by any regulator for human use. Source: PubChem CID 125672 (MSH 11-13), 2026; CAS 67727-97-3; Wikipedia, "KPV tripeptide," 2026.

Where does KPV come from in α-MSH biology?

KPV is the last three amino acids of α-melanocyte-stimulating hormone (α-MSH), a hormone in the melanocortin system best known for affecting skin pigmentation and appetite. When that 13-amino-acid hormone is trimmed down to its final fragment, what remains is KPV, which appears to keep the anti-inflammatory signaling while shedding the pigment and appetite effects. That separation is exactly why it is studied on its own.

α-MSH itself is produced from a larger precursor protein (proopiomelanocortin, or POMC) and acts through melanocortin receptors, a family of G-protein-coupled receptors found throughout the body (Annals of the Rheumatic Diseases, "α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs," 2007, retrieved 2026-06-16). The same review notes that the C-terminal tripeptide of α-MSH, KPV, "exhibit[s] anti-inflammatory properties as seen for α-MSH," which is the core reason a three-amino-acid fragment is taken seriously at all.

This melanocortin connection is also why KPV sits in the same family conversation as the tanning peptides. α-MSH is the natural hormone that the synthetic compounds melanotan I and melanotan II are designed to mimic for pigmentation, while KPV is the opposite end of the molecule: the anti-inflammatory tail rather than the pigment-driving core. We keep that relationship brief here because the pigmentation side is its own topic.

Our take: The cleanest way to hold KPV in your head is "the anti-inflammatory tail of a tanning hormone." It comes from the same parent molecule as the melanotan peptides, but it was deliberately isolated to keep the immune-calming signal and drop the pigment and appetite effects. That selective design is the whole appeal, and also why it is studied separately from α-MSH.

How does KPV work?

KPV is proposed to calm inflammation mainly by getting inside cells and blocking NF-κB, a master switch that turns on inflammatory genes, which in turn lowers the production of pro-inflammatory signaling molecules. In the gut, it appears to be carried into intestinal cells by a transporter called PepT1. This picture comes from cell and animal studies, not human trials.

In plain terms, inflammation is partly run by a control protein called NF-κB. When NF-κB moves into a cell's nucleus, it switches on genes that produce inflammatory messengers. The leading idea is that KPV interferes with that step. A 2007 review describes how α-MSH and its fragments lead to "significant downregulation of pro-inflammatory cytokines such as IL1β, IL6 and TNFα" and notes that α-MSH "inhibits the nuclear translocalisation of the active p65/p50 NF-κB heterodimer," the molecular move that would otherwise switch those genes on (Annals of the Rheumatic Diseases, 2007, retrieved 2026-06-16).

The gut findings add a second piece. In a 2008 study, researchers reported that KPV is taken up by intestinal epithelial cells through the PepT1 peptide transporter, and that once inside, nanomolar amounts inhibited NF-κB and MAP-kinase inflammatory signaling (Gastroenterology, "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation," 2008, retrieved 2026-06-16). Here is what each proposed mechanism contributes, in simple terms:

• NF-κB inhibition: KPV is reported to block the activation of NF-κB, the switch that turns on inflammatory genes, which is the most consistently described mechanism.
• Cytokine downregulation: by quieting NF-κB, it is associated with lower levels of inflammatory messengers such as IL-1β, IL-6, and TNF-α.
• PepT1-mediated uptake (gut): in intestinal cells, KPV appears to ride the PepT1 transporter into the cell, which is notable because PepT1 is upregulated in inflamed bowel tissue.
• MAP-kinase signaling: the 2008 study also reported effects on MAP-kinase inflammatory pathways alongside NF-κB.

The deeper receptor-and-signaling questions (exactly how NF-κB is regulated, how PepT1 transport is controlled) are their own topic. We keep them at overview level here and link out to how peptides work for the foundations.

What is KPV studied for?

KPV is studied mainly for gut inflammation (colitis and inflammatory bowel disease models), skin inflammation and wound healing, and antimicrobial activity, with anti-inflammatory action as the common thread. None of these are FDA-approved uses; they are the directions cell and animal research have pointed.

The most developed line of research is the gut. Because KPV can enter intestinal cells through the PepT1 transporter, which is itself increased in inflamed bowel tissue, it has been tested in rodent models of colitis, where oral KPV reduced intestinal inflammation (Gastroenterology, 2008, retrieved 2026-06-16). The second well-known angle is the skin: in a 2025 keratinocyte study, KPV reduced inflammation and cell damage by modulating the MAPK and NF-κB pathways, which is why it appears in topical and dermatology-adjacent discussions (Wikipedia, "KPV tripeptide", retrieved 2026-06-16). A quick overview of the areas KPV is studied for, and where the evidence stands:

Because each of these is a distinct potential future spoke, we keep them brief here. The honest headline: KPV is interesting across several inflammation-related areas in the lab, but the human evidence has not been built yet.

How strong is the evidence for KPV?

The evidence for KPV is genuinely interesting but almost entirely preclinical: cell and rodent studies, with essentially no completed human clinical trials. That gap between promising lab results and an empty human file is the single most important thing to understand before considering it.

The foundational findings are real and peer-reviewed. The 2007 review establishes the anti-inflammatory framing and NF-κB story for α-MSH peptides including KPV (Annals of the Rheumatic Diseases, 2007, retrieved 2026-06-16), and the 2008 Gastroenterology study provides the gut-uptake-and-colitis evidence in mice (Gastroenterology, 2008, retrieved 2026-06-16). What is missing is the next step: human trials. No FDA-approved use exists, and KPV is catalogued among compounds with no formal legal status, sold for research use only (Wikipedia, "KPV tripeptide", retrieved 2026-06-16).

Why the human evidence is so thin

It helps to be specific about what does and does not exist. The KPV literature is built on in vitro work (cells in a dish) and rodent models (mainly mice with chemically induced colitis), plus more recent cell work in skin. There is no large, well-designed randomized controlled trial of KPV in people, which is the kind of study that would actually establish whether it works, in whom, and at what dose. There is also very little human pharmacokinetic data, meaning we do not really know how much of an injected, oral, or topical dose reaches its target, how long it lasts, or how it is cleared in humans. That missing pharmacokinetic picture is part of why every dose figure in this guide can only be a reported convention rather than a validated number.

This matters for a practical reason. Strong signals in mice frequently fail to reproduce in humans, and a three-amino-acid peptide is no exception to that rule. For a reader, the honest takeaway is that KPV sits firmly in experimental territory: it is not FDA-approved, it has never cleared a real efficacy trial in people, and any decision to use it is being made without the safety net that an approved medicine provides.

Our take: KPV's preclinical story is cleaner and more mechanism-driven than a lot of trendy peptides, which is genuinely appealing. But "clean mechanism in mice" is not "proven in humans." The most common mistake we see is people reading the gut-colitis result as if it were a human IBD trial. It is not, and treating it that way is how people get hurt.

What doses of KPV do people report using?

There is no validated dose for KPV, but reported research and community protocols cluster around 200 to 500 mcg per day by subcutaneous injection, with oral and topical use also discussed. These are figures people report, not an established or recommended dose, and there is no approved label to anchor them.

The most commonly cited range in community and clinic write-ups is roughly 200 to 500 mcg per day subcutaneously, often once daily, sometimes split, and frequently run in short cycles. Oral capsules are also discussed, leaning on the gut research and the PepT1 uptake finding, and topical preparations come up because of the skin work. We label all of this as a community and research convention because no regulator has reviewed a dose, the underlying human pharmacokinetics are essentially unstudied, and the published science used controlled laboratory amounts in cells and mice rather than human dose-finding (Gastroenterology, 2008, retrieved 2026-06-16). For orientation only, here is how people commonly describe the reported routes (not a recommendation):

The detailed titration ladder, reconstitution math, and route-specific handling are a dedicated future spoke. We cover only the high-level framing here and link out to the general how peptides work foundations and the quality groundwork below.

Our take: Numbers like "300 mcg a day" circulate on vendor pages until they sound official. They are not. They are community conventions, not human dose-finding results, which is exactly why we never present them as a validated dose. The peer-reviewed studies measured KPV in cells and mice, not in a person deciding how much to inject.

What are the side effects of KPV?

Because KPV has essentially never been tested in humans, its true side-effect profile is unknown; reported issues are mostly mild and anecdotal, such as injection-site reactions. "Unknown" is the honest headline, not "safe."

In the preclinical literature, KPV has generally been described as well tolerated in the cell and animal models used, and its anti-inflammatory framing is part of its appeal (Annals of the Rheumatic Diseases, 2007, retrieved 2026-06-16). But "tolerated in mice and cells" is not the same as a human safety profile, and there is no body of human adverse-event data to draw on. A hub-level overview of what is reported and what is unknown:

• Commonly reported (mild, anecdotal): injection-site redness, swelling, or irritation; occasional headache or fatigue. These are community reports, not trial data.
• Quality-related risks: because the market is unregulated, contamination, mislabeled potency, or impurities are real concerns independent of the peptide itself.
• Theoretical: because KPV broadly dampens inflammatory signaling, suppressing a normal immune response is a reasonable concern to raise, though it has not been characterized in humans.
• Unknown: true long-term human safety, because the long-horizon data simply do not exist.

This is the hub-level summary. For how to think about source quality and contamination risk, the most useful next read is how to vet peptide quality.

How is KPV different from BPC-157?

KPV and BPC-157 are often mentioned together for gut health, but they are different tools: KPV is an anti-inflammatory α-MSH fragment that works by quieting inflammatory signaling (NF-κB), while BPC-157 is a larger gastric peptide studied mainly for tissue repair through new blood-vessel growth. Both are unapproved research compounds with limited or absent human data.

The cleanest way to hold them apart is by job and origin. KPV is a three-amino-acid fragment of the hormone α-MSH, and its leading proposed action is anti-inflammatory: blocking NF-κB and lowering inflammatory cytokines (Annals of the Rheumatic Diseases, 2007, retrieved 2026-06-16). BPC-157 is a 15-amino-acid peptide derived from a protein in gastric juice, and its leading proposed action is tissue repair, chiefly through angiogenesis (building new blood vessels at an injury site). So at a high level: KPV is the inflammation-calming peptide, and BPC-157 is the tissue-repair peptide. They are sometimes discussed as complementary in gut contexts precisely because their proposed mechanisms differ rather than overlap.

That is the hub-level contrast, and it is deliberately brief to avoid overlapping our dedicated BPC-157 guide. For the full picture of the repair peptide, including its mechanism, evidence, dosing, and legal status, see our complete guide: BPC-157: the complete guide to the healing peptide.

Our take: People often pair KPV and BPC-157 and assume they do the same thing. They do not. If you remember one line, make it this: KPV is proposed to turn inflammation down, BPC-157 is proposed to turn repair up. That difference, not similarity, is the whole reason anyone discusses them together.

Is KPV safe and legal?

KPV is not approved by any regulator, so there is no official safety determination, and it is not legal to sell or prescribe as an approved medicine or to include in dietary supplements; the products sold online are unapproved "research chemicals." That status matters more than any single study.

On safety, the preclinical data look benign for an investigational compound, but "tolerated in cells and mice" is not the same as "established safe in people," and there is no human safety dataset to point to. On legality, KPV has no FDA-approved use and is catalogued among compounds with no formal legal status, sold strictly for research use only and not for human consumption (Wikipedia, "KPV tripeptide", retrieved 2026-06-16). It is not a recognized dietary ingredient, and there is no legitimate prescription route for an unapproved peptide outside of a clinical trial. For the broader legal framework and how to evaluate a vendor, see are peptides legal and how to vet peptide quality.

Our take: The single most common misunderstanding is assuming that because KPV is sold openly online, it must be legal and vetted to use. It is sold "for research use only," it is unapproved, and it has no human safety file. Easy to buy is not the same as legal or safe.

How do people obtain KPV?

Because KPV is unapproved, the main way people access it is by buying unapproved "research chemical" vials, capsules, or topical preparations online, which is a legal and safety gray market. There is no legitimate "get a prescription" route for an unapproved peptide outside of a clinical trial.

The research-peptide market is where most online searches end up: vendors sell lyophilized KPV "for research use only," and buyers reconstitute and use it off-label. That market carries real risks of mislabeled potency, impurities, and non-sterile product, with no regulatory oversight (Wikipedia, "KPV tripeptide", retrieved 2026-06-16). If you are researching that path despite the risks, the responsible groundwork is the same as for any research peptide:

1. Confirm the legal status for your country and situation, including sport and workplace rules. See are peptides legal.
2. Demand a certificate of analysis (COA) from independent third-party testing, and learn to read it for identity and purity. See how to vet peptide quality.
3. Understand handling before anything else. Reconstitution and cold storage are not optional, and the basics of how short peptides behave matter. See how peptides work.
4. Talk to a qualified clinician who can weigh your specific health situation, interactions, and contraindications.

We are describing what people do, not endorsing it. Using an unapproved peptide means accepting unknown risks with no regulatory safety net.

Frequently Asked Questions

The bottom line

KPV is one of the more scientifically tidy stories in the research-peptide world. It is a three-amino-acid fragment of α-MSH that seems to keep the parent hormone's anti-inflammatory signaling, blocking NF-κB and lowering inflammatory cytokines, while shedding the pigment and appetite effects. The gut work, where it rides the PepT1 transporter into intestinal cells and calms colitis in mice, is a genuinely elegant result, and the more recent skin findings add a second front. That mechanistic clarity is the real reason KPV earned its anti-inflammatory reputation.

The other half of the story is discipline. KPV is unapproved, has essentially no human evidence, and is sold only as an unregulated research chemical with no guarantee of what is in the vial. A clean mechanism in mice is not a proven, safe therapy in people, and KPV has never been through the human trials that would close that gap. The honest label is investigational. If you take one thing from this hub, let it be the distance between "promising in cells and rodents" and "proven and safe in humans," and the value of a qualified clinician in navigating it. From here, the natural next reads are how peptides work, how to vet peptide quality, and are peptides legal.

Sources

• PubChem. "Compound Summary for CID 125672 (MSH 11-13 / KPV)." Retrieved 2026-06-16. https://pubchem.ncbi.nlm.nih.gov/compound/125672
• Wikipedia. "KPV tripeptide." Retrieved 2026-06-16. https://en.wikipedia.org/wiki/KPV_tripeptide
• Luger, T.A., Brzoska, T. "α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs." Annals of the Rheumatic Diseases, 2007. Retrieved 2026-06-16. https://pmc.ncbi.nlm.nih.gov/articles/PMC2095288/
• Dalmasso, G., Charrier-Hisamuddin, L., Nguyen, H.T.T., Yan, Y., Sitaraman, S., Merlin, D. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology, 2008;134(1):166-178 (PMID 18061177). Retrieved 2026-06-16. https://pubmed.ncbi.nlm.nih.gov/18061177/
• "Anti-inflammatory and antifungal activity of the (CKPV)₂ peptide against Candida albicans." PMC, 2013. Retrieved 2026-06-16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573073/